Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: MarketLine (a Datamonitor Company)
$175.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Dainippon Sumitomo Pharma Co Ltd's Subsidiary Files Two Supplemental New Drug Applications Seeking Approval for the use of Latuda® (lurasidone HCl)


Thursday, 6 Sep 2012 07:30pm EDT 

Dainippon Sumitomo Pharma Co Ltd announced that its subsidiary, Sunovion Pharmaceuticals Inc., has submitted two supplemental New Drug Applications (sNDAs) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of LATUDA (lurasidone HCl) as 1) monotherapy and 2) adjunctive therapy to lithium or valproate, both to treat adult patients with depressive episodes associated with bipolar I disorder (bipolar depression). These sNDAs are supported by two 6-week, double-blind, placebo-controlled Phase 3 clinical trials, PREVAIL 1 and PREVAIL 2 (PRogram to EValuate the Antidepressant Impact of Lurasidone), involving 852 patients with bipolar depression. 

Related Company News

Company Quote

1219.0
0.0 +0.00%
2:00am EDT